Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome

• Published in: Leukemia & lymphoma 2019-02, Vol.60 (3), p.703-710
• Main Authors: Mashima, Kiyomi, Ikeda, Takashi, Toda, Yumiko, Ito, Shoko, Umino, Kento, Minakata, Daisuke, Nakano, Hirofumi, Morita, Kaoru, Yamasaki, Ryoko, Kawasaki, Yasufumi, Sugimoto, Miyuki, Ashizawa, Masahiro, Yamamoto, Chihiro, Fujiwara, Shinichiro, Hatano, Kaoru, Sato, Kazuya, Oh, Iekuni, Ohmine, Ken, Muroi, Kazuo, Kanda, Yoshinobu
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy; Blood Transfusion; Bone Marrow - pathology; Bone Marrow Cells - metabolism; Bone Marrow Cells - pathology; erythroid hyperplasia; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic syndromes; Myelodysplastic Syndromes - blood; Myelodysplastic Syndromes - diagnosis; Myelodysplastic Syndromes - genetics; Myelodysplastic Syndromes - therapy; non-erythroid cells; Prognosis; relapse; Retrospective Studies; RNA, Messenger - genetics; ROC Curve; Transplantation, Homologous; WT1; WT1 Proteins - blood; WT1 Proteins - genetics
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428194.2018.1504940

Wilms tumor gene 1 (WT1) is highly expressed in myelodysplastic syndrome (MDS) cells and is known to reflect the tumor burden in MDS. We evaluated the usefulness of WT1 mRNA levels for predicting the prognosis of MDS. At diagnosis, WT1 levels were strongly correlated with the percentage of blasts calculated based on non-erythroid cells, but not with that based on all nucleated cells (r = 0.57, p